Taysha Gene (TSHA) news

Taysha Gene Therapies Q2 EPS USD -0.13

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) reported a net loss of $26.9 million for the second quarter of 2025, translating to an EPS loss of $0.09 . This represents an increase in the net loss compared to $20.9 million, or $0.09 per share, in the same period in 2024 . The company’s research and…

Taysha, Cytaleant sign commercial supply pact for TSHA-102

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) has entered into a commercial supply agreement with Cytaleant, a contract development and manufacturing organization (CDMO), to support the production of TSHA-102, its lead gene therapy candidate for Rett syndrome. The agreement is intended to facilitate…

Taysha Gene Therapies prices offer stock, pre-funded warranty

Taysha Gene Therapies prices $32.5M stock offering at $6.00/shr

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of a public offering of 46,868,687 shares of its common stock at $2.75 per share, with an option for certain investors to receive pre-funded warrants to purchase 25,858,586 shares at $2.749 per warrant. The offering is expected to…

Taysha Gene Therapies Inc: Files for mixed shelf offering of up to $200 mln - SEC filing

Taysha Gene Therapies Inc. (Nasdaq: TSHA) has announced the pricing of an underwritten public offering of 46,868,687 shares of its common stock at a price of $2.75 per share, with an option for certain investors to receive pre-funded warrants to purchase 25,858,586 shares at $2.749 per warrant. The…